The Los Angeles Post
U.S. World Business Lifestyle
Today: March 29, 2025
Today: March 29, 2025

US Senator Sanders says generic drugmakers could sell Ozempic for less than $100/month

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London
September 17, 2024
Reuters - Reuters

(Reuters) - U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month.

WHY IT'S IMPORTANT

Novo Nordisk CEO Lars Jorgensen is set to testify before the Senate Committee on Health, Education, Labor and Pensions (HELP), which Sanders chairs, in a hearing next week focusing on U.S. prices for its widely popular Ozempic and weight-loss drug Wegovy.

KEY QUOTE

Sanders said he spoke to the chief executives of several major generic drugmakers over the past few months.

"They have studied the matter and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 per month," he said.

Sanders did not name the companies to which he spoke. Ozempic's patent is not set to expire in the United States until 2032.

CONTEXT

Ozempic, which has the same active ingredient as Wegovy and is used off-label for weight loss, belongs to the popular GLP-1 class, which has seen overwhelming demand in the United States.

Some analysts have forecast the total market for weight-loss drugs to reach $150 billion by the early 2030s.

However, this comes amid criticism from lawmakers over the high costs associated with these medications.

BY THE NUMBERS

A month's supply of Novo's Ozempic carries a U.S. list price of $935.77 while Wegovy lists for $1,349.02 per month, according to the drugmaker's website, although most consumers pay less.

(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

Related Articles

Wegovy diet plan: What foods to eat and avoid while taking semaglutide Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump Catalent misses Q1 revenue estimates ahead of $16.5 billion deal close with Novo Holdings
Share This

Popular

Business|Political|Technology|US

Musk to visit CIA on Monday, spokesperson says

Musk to visit CIA on Monday, spokesperson says
Business|Political|US

Judges block Trump orders targeting two law firms as Skadden cuts deal

Judges block Trump orders targeting two law firms as Skadden cuts deal
Business|Economy|Technology|US

Musk's xAI buys Musk's X social media platform for $33 billion

Musk's xAI buys Musk's X social media platform for $33 billion
Arts|Business|Economy|Entertainment|Travel

What to know about Boulder, Colorado, the Sundance Film Festival's new home

What to know about Boulder, Colorado, the Sundance Film Festival's new home

Economy

Americas|Crime|Economy|Political|World

Noem ends her first visit to Latin America in Mexico to discuss crime and migration

Noem ends her first visit to Latin America in Mexico to discuss crime and migration
Business|Economy|Political|US

Trump says he is willing to make deals on tariffs

Trump says he is willing to make deals on tariffs
Business|Celebrity|Economy|Science|Technology

Elon Musk sells X to his own xAI for $33 billion in all-stock deal

Elon Musk sells X to his own xAI for $33 billion in all-stock deal
Americas|Business|Economy|Finance|Political

Brazil's Lula will not take unorthodox measures ahead of election, minister says

Brazil's Lula will not take unorthodox measures ahead of election, minister says

Access this article for free.

Already have an account? Sign In